La catena delle opzioni mostra i dati chiave delle opzioni azionarie di CASI Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per CASI Pharmaceuticals..

CASI Pharmaceuticals (NASDAQ:CASI) Azioni, Catena delle Opzioni

CASI Pharmaceuticals

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals Inc

Casino Guichard-Perrachon SA

CASINO GUICHARD PERRACHON by Casino Guichard Perrachon SA

Casino Guichard-Perrachon SA ADR

CASIO COMPUTER CO LTD by Casio Computer Co., Ltd.

Casio Computer Co Ltd

CASIO COMPUTER UNSP/ADR by Casio Computer Co., Ltd.

Press Releases

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Small Cap

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Ligand Reports Second Quarter 2024 Financial Results

Earnings

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

News

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

AGEN

AMGN

CASI

LGND

MRNS

OVID

PIRS

TVTX

VKTX

VRNA

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Aligos Therapeutics

Allakos

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kezar Life Sciences

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lantern Pharma

OS Therapies

Pluri

Radiopharm Theranostics Limited - American Depositary Shares

Comments

CASI Pharmaceuticals

CASI Pharmaceuticals (CASI) Opzioni

CASI Pharmaceuticals (NASDAQ:CASI) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO